Conference abstract · 10 Apr 2025
Conference abstractPublished 2017
Developing novel, technology-derived endpoints for use in clinical trials
Foundation for Prader Willi Research, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Mobile technology offers new ways to capture objective measurements as clinical trial participants go about their daily lives by utilizing novel endpoints, defined as new endpoints that have not previously been possible to assess or existing endpoints that can be measured in new and possibly better ways. These novel endpoints have the potential to provide high-quality data pertaining to outcomes that are meaningful to patients while enabling larger trials with reduced barriers to participation, making possible more sensitive, generalizable and patient-centric assessments. However, the pathway for selecting and developing technology-derived endpoints to support regulatory approval and labeling claims is not currently well-described. Methodology & Theoretical Orientation: The Clinical Trials Transformation Initiative (CTTI) established a project team comprised of regulators, industry experts, academics and patient representatives. This team hosted workshops to write four use cases outlining the development of novel, technology-derived endpoints and conducted a systematic literature review. Findings: CTTI proposes recommendations and tools to support the selection, development and application of novel mobile endpoints. In addition to the recommendations, tools include a novel endpoint development benefit framework; a selection tool to support decisions between viable novel endpoints for development; a guide to interacting with FDA; flowchart of steps for novel endpoint development; a supporting tool for these steps describing suggested approaches and considerations; use cases providing tangible examples of novel endpoint development (Parkinson’s disease, diabetes, heart failure, Duchenne muscular dystrophy). Conclusion & Significance: Novel, technology-derived endpoint development may be particularly valuable in rare disease research where there is significant unmet need for quality measures and where the possibility of hybrid or decentralized trials may facilitate recruitment that has been impossible to date. The CTTI recommendations and tools provide an important resource to support efforts to develop these endpoints and realize these benefits.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 27 Aug 2024
Novel Antifibrotic Agents in the Treatment of Diabetic Nephropathy: A Clinical Trial Analysis
Commentary · 30 May 2022
Imaging Biomarkers are Frequently Root Contributors to a Clinical Trial’s Endpoints
Short communication · 14 Feb 2021
Clinical surveillance to monitor and maximize efficacy in primary endpoints in epilepsy trials
Conference abstract · 19 Sep 2019
Clinical surveillance to monitor and maximize efficacy in primary endpoints in epilepsy trials
More from this journal
The newest in Andrology & Gynecology: Current Research.
Research article · 30 Jun 2026
NOA-SERA: Combined Autologous Progenitor Cells and Platelet-Derived Growth Factors for Male Factor Infertility Due to Non-Obstructive Azoospermia (NOA) and Severe Oligoasthenoteratozoospermia (OATS)-A Case Series
Editorial · 28 Mar 2025
Advances in Male Infertility Diagnosis and Treatment: A Contemporary Overview
Editorial · 28 Mar 2025
Advances in Urogenital Surgery: Minimally Invasive Techniques in Andrology and Gynecology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAndrology & Gynecology: Current Research
- SubjectNephrology & Urology
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Theresa Strong”

